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Background: Induced sputum (IS) sampling is a safe and validated approach to study
bronchial inflammation in chronic obstructive lung diseases. Although promising results
have also been reported in various diffuse interstitial lung disorders, the potential use of IS
in the assessment of connective tissue diseases (CTD)-related lung involvement has not yet
been investigated.
Aim of the study: To evaluate the clinical usefulness of IS in the early management of
patients suffering from rheumatoid arthritis (RA) and systemic sclerosis (SSc) at the onset
of respiratory symptoms.
Patients and methods: The study population included 19 patients (RA ¼ 12; SSc ¼ 7) and
14 age- and sex-matched healthy volunteers. Lung function testing, high resolution
computed tomography (HRCT) of the thorax and IS collection were performed in all cases.
Broncho-alveolar lavage (BAL) was obtained in selected patients.
Results: IS samples from patients contained a significantly higher percentage of
neutrophils and a lower percentage of macrophages compared to healthy subjects
(p ¼ 0.002 and 0.001, respectively), while the total cell number showed no differences. In
addition, sputa yielded both higher cell counts and higher neutrophils than BAL samples
(p ¼ 0.02 in all instances). No correlations were found between IS findings and lung
function parameters, HRCT and BAL findings.Elsevier Ltd. All rights reserved.
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CTD patients with early clinical evidence of lung involvement. Future studies are needed
to determine whether the assessment of airway inflammation adds significant information
that may result in a relevant improvement of disease management.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Lung involvement is a quite frequent feature of connective
tissue diseases (CTD). Diffuse interstitial lung disease (ILD) is
the most common pulmonary manifestation in patients
affected by rheumatoid arthritis (RA), being a progressive
disease often leading to severe symptoms and respiratory
failure.1 Prevalence of ILD in RA varies according to the
diagnostic criteria used, ranging from low rates, based on
conventional chest X-ray, to up to 71%, based on the evidence
of alveolitis.2 Pulmonary fibrosis is even more common in
systemic sclerosis (scleroderma-SSc) as it plays an important
role in the disease prognosis and outcome, suggesting that
early detection of lung abnormalities is of high priority.3
Several possibilities are available for the assessment of
interstitial lung involvement in the course of CTD. Unlike
chest radiography which may be normal in symptomatic
patients, thoracic high resolution computed tomography
(HRCT) is more sensitive and accurate in detecting early
changes of lung fibrosis.4,5 In a similar manner, unlike
decreased forced vital capacity (FVC) and total lung
capacity (TLC), the single breath diffusion capacity of the
carbon monoxide (DLCOsb) has been demonstrated to be a
highly sensitive method and an appropriate tool for the
detection of early lung involvement.6 Evaluation of diffusion
capacity may however not provide enough information on
the extent of lung inflammation and fibrosis. In this issue,
broncho-alveolar lavage (BAL) collection is regarded as a
safe and inexpensive procedure for the investigation of
various forms of ILDs and their activity.5 In SSc, even single-
site BAL usually correctly detects the presence of alveolitis.7
BAL is often abnormal in asymptomatic patients with early
alveolitis who have normal chest radiographs, providing
information about the nature of the ongoing subclinical
disease that may be useful for the estimation of prognosis
and choosing the appropriate treatment.5,8
Sputum induction by hypertonic solution is a validated
method to study bronchial inflammation in chronic obstruc-
tive pulmonary diseases (COPD), including asthma and
chronic bronchitis.9–11 Unlike mucosal biopsies and BAL,
whose sampling requires more invasive procedures, collec-
tion of induced sputum (IS) has been shown to be safe and
well tolerated irrespective of the method used.12 IS has
already provided promising results in patients with ILDs,13,14
including pneumoconiosis,15,16 sarcoidosis,17,18 hypersensi-
tivity pneumonitis,19 non granulomatous ILDs,20 and lung
involvement in Crohn’s and Fabry’s diseases.21,22 However,
to our knowledge, the potential use of IS in the assessment
of pulmonary inflammation in CTD has been poorly investi-
gated until now.23
Aim of the present study was to evaluate the cellular
pattern and clinical usefulness of IS in the early manage-ment of patients suffering from CTD, including RA and SSc,
at the onset of respiratory symptoms. Moreover, we asked
whether IS findings were correlated with lung function, X-
ray and BAL data.
Methods
Study population
The study population included 19 patients meeting the
criteria for the diagnosis of RA (n ¼ 12) and SSc (n ¼ 7).24,25
All patients were enrolled at the Division of Rheumatology of
the University ‘‘Federico II’’ of Naples and referred to the
Division of Respiratory Diseases of the same University at the
Monaldi hospital, Naples, Italy. The control group included
14 healthy volunteers recruited among hospital staff. The
study was approved by the local Ethics Committee and all
subjects gave written consent.
Pulmonary function tests
Spirometry and haemoglobin (Hb)-adjusted-DLCOsb were
performed using a computer-assisted spirometer (Master
Screen Diffusion, Jaeger, Wuerzburg, Germany) according to
the American Thoracic Society/European Respiratory So-
ciety standards.26–28 Arterial blood gases were analysed at
rest while subjects were breathing ambient air (FiO2 21%).
Radiology
HRCT was realized with 1mm thick sections at 10mm
intervals with prone slices to exclude dependent changes.
CT scans were analysed according to the method of Remy
Jardin and given a semi-quantitative score for the presence
or absence of changes compatible with fibrosis or ground
glass attenuation (0 ¼ absent; 1 ¼ mild; 2 ¼ moderate;
3 ¼ severe).29
Induced sputum collection and processing
Sputum induction was performed using a modification of the
method described by Fahy et al.30 Briefly, following pre-
medication with 200 mg salbutamol, all subjects inhaled 3%
hypertonic saline solution generated by a DeVilbiss 65
ultrasonic nebulizer (DeVilbiss Corporation, Somerset, PA,
USA) with a mean volume output of 2.4mL/min. Through-
out the procedure, subjects were encouraged to cough and
to expectorate into a sterile plastic container. Ten minutes
after the start of nebulization and every 5min thereafter,
they were asked to rinse their mouths with normal saline to
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monitoring was performed before and after each inhalation.
Nebulization was stopped after 20min or earlier if the FEV1
value fell by at least 15% from baseline or if troublesome
symptoms occurred.
Sputum samples (total volume of at least 2mL) were
processed within 2 h after collection. An equal volume
of freshly prepared 0.1% dithiothreitol (DTT—Sigma
Chemical Co., St Louis, MO, USA) was added and samples
were incubated at 37 1C for 30min. Ten microliters of
each sample were used to determine the total cell
count expressed as number of cells 106/mL. The remaining
sputum was then washed with 5% foetal calf serum
(FCS)-enriched phosphate-buffered saline (PBS) solution
and centrifuged at 1200 rpm for 10min. The supernatant
was removed while cell pellets were washed twice
with PBS (without Ca2+ and Mg2+). Cytocentrifugates were
stained by the May–Grunwald–Giemsa method. The
differential cell count of macrophages, neutrophils, lym-
phocytes, eosinophils and epithelial cells was made under a
light microscope (magnification 1000) by counting at least
400 cells. A cut-off of 20% squamous cells was used for
defining adequate samples.11 All analysed sputa were
suitable, as patients not able to expectorate adequate
sputum samples were initially excluded from the study
population.Table 1 Demographics of the study population.BAL collection and processing
BAL collection was performed as previously described.31
Briefly, three 50mL aliquots of 0.9% saline solution were
instilled through a flexible bronchoscope (Olympus BF 240,
Tokio, Japan) in a segmental or sub-segmental bronchus of
the involved lung lobe following local xylocaine anaesthesia.
Samples were filtered through a sterile two-layer cotton
gauze to remove mucus and centrifuged at 1000 rpm for
10min at 4 1C. Recovered cells were resuspended in RPMI
1640 medium and counted. Cell viability (490%) was
determined by trypan blue exclusion assay. Staining with
May–Grunwald–Giemsa was performed to evaluate the
leukocyte differential count.Healthy controls 14
Gender, F:M 8:6
Age, yearsy 4179.5 (37; 35–46.7)
Smoking status 2 (14)
Patients 19
Gender, F:M 12:7
Age, yearsy 48.7713.3 (54; 39.7–60)
Smoking status 3 (16)
AR 12 (63)
SSc 7 (37)
Disease duration, yearsy 3.472.1
Anti-rheumatic therapy,z 19
Data are expressed as n (%).
yData are expressed as mean value7SD (median value; IRQ
25–75).
zTreatment regimens included non steroid-anti-inflamma-
tory drugs, corticosteroids, methotrexate, cyclophospha-
mide, and chloroquine.Flow cytometric analysis of T cell subsets
One aliquot of processed sputum or BAL samples was
reserved for T cell subsets evaluation. Flow cytometry was
performed on a FACScan equipped with an Argon laser
(Becton-Dickinson, Mountain View, CA, USA). Data were
analysed using the Cell Lysis II program (Becton-Dickinson).
The selection of the lymphocyte population was based on
side scatter and expression of CD45. Lymphocytic T subsets
were identified by monoclonal antibodies (Mo Abs) as
follows: CD3 for total lymphocytes; CD4 and CD8 for T cells.
Mo Abs were directly conjugated to either fluorescein
isothiocyanate (FITC) or phycoerythrin (PE). Cells were
incubated for 30min and read either immediately or after
24 h. Matched isotype Abs were used as negative controls.
All Abs used were purchased from Becton Dickinson.Statistical analysis
Descriptive statistics were used to analyse continuous
variables. Differences between lung function parameters
from patients and controls were performed with the
Student’s t-test. Differences between cell counts and
differentials in IS and BAL samples from patients and healthy
controls were analysed with the Mann–Whitney U-test. The
Wilcoxon test was used to compare differences in differ-
ential counts and cell subsets in IS and BAL from patients.
Correlations between different cell subsets in different
samples from patients were examined by Pearson’s correla-
tion coefficient. Spearman’s rank correlation was used to
evaluate any relationship between cell subsets, lung
function parameters and thoracic HRCT findings. A p value
o0.05 was considered significant. All analyses were per-
formed with the SPSS.11 software.Results
Demographics
Demographic characteristics of the study population are
reported in Table 1. As no significant differences were found
by comparing patients with AR with those affected by SSc,
all of them were considered as a unique group. Patients with
no previous history of lung diseases were included in the
study early at the onset of pulmonary symptoms, which
mainly included non-productive cough (47%) and/or dys-
pnoea upon exertion (63%). Respiratory infections, at least
in the previous 2 months, were ruled out in all cases. At
enrolment, all patients were under treatment with oral non-
steroid anti-inflammatory drugs (diclofenac: n ¼ 2; indo-
methacin: n ¼ 1) or corticosteroids (prednisone: n ¼ 16) in
association, in same instances, with other immunosuppres-
sive drugs (methotrexate: n ¼ 4; cyclophosphamide: n ¼ 6;
cloroquine: n ¼ 5).
ARTICLE IN PRESS
A. Vatrella et al.1386Lung physiology
Results of lung function testing are shown in Table 2.
A mild to moderate restrictive ventilatory pattern
was detected in patients as compared to controls
due to the reduction of FEV1, FVC, and TLC values (%
predicted) (po0.0001 and 0.002, respectively), while no
differences were found by comparing the Tiffenaux index.
To date, airflow obstruction (FEV1/FVCo70%) was evident
in only 3 cases (16%). Interestingly, more than half of
patients showed a significant reduction of FEF25–75 values
(po0.0001). Not surprisingly, the Hb-adjusted-DLCOsb
values were significantly lower in patients than in control
subjects (p ¼ 0.002), being o50% of predicted in four
cases (21%).Radiology
Lung HRCT was performed as part of a routine clinical
protocol. Abnormalities compatible with interstitial lung
disease, that are ground glass attenuation and thickened
septal lines (scores ¼ 1 and 2), were detected in more than
half patients (respectively in 32% and 26% of cases). No
evidence of end-stage lung fibrosis was found (score ¼ 3) in
any case. No abnormalities were found in 42% patients
(score ¼ 0). Additional findings included pleural effusion in 2
AR patients.Table 2 Lung function testing.
Parameter Controls (n ¼ 14)
PaO2, mmHg at rest (21% FiO2) nd
z
FEV1, % predicted 10478 (105; 100–1
FVC, % predicted 10377 (100; 98–10
FEV1/FVC, % 8472 (84; 83–85)
FEF25–75, % predicted 112713 (110; 103–
TLC, % predicted 10175 (100; 97–10
DLCOsb, % predicted 10376 (103; 97–10




Table 3 Induced sputum differential cell count.
Cells 106/ml % macrophages % lymp
Controls (n ¼ 14) 672.9 60.6718.6 2.271.
(4.2; 3.5–7.5) (67.5; 52–71.5) (2; 1.2
Patients (n ¼ 19) 7.274.7 35711 3.571.
(5.5; 3.2–9.9) (30; 25–42) (3; 2–4
py nsz 0.001 0.042
Data are expressed as mean value7SD (median value; IRQ 25–75
yMann-Whitney U-test.
zns ¼ not significant.Induced sputum
Total and differential (%) cell counts in IS from patients and
healthy controls are shown in Table 3. All subjects tolerated
well sputum induction without experiencing adverse events.
The number of total cells ( 106/ml) was not different in
patients compared to controls. However, both the percen-
tage and the absolute number of neutrophils were signifi-
cantly higher in patients (p ¼ 0.002 and 0.02, respectively),
while the percentage of macrophages was lower as
compared to controls (p ¼ 0.001). No other significant
differences were found between the two study groups for
any cell type. No correlation was found between the
neutrophil differential percentages in IS and any lung
function parameter or thoracic HRCT finding (n ¼ 19).
Broncho-alveolar lavage
In order to investigate features of pulmonary inflammation
to be compared with IS findings, patients with HRCT
evidence of lung involvement were asked to be submitted
to FBS for BAL collection. Two patients out of 11 refused the
exam. Data are reported in Table 4. The comparison of the
total cell number recovered in IS and BAL samples from the 9
patients studied demonstrated that sputa yielded higher cell
counts (po0.02). When looking at cell differentials, a
neutrophil alveolitis (neutrophils 410%) was present in 8
patients (88%), being more than 20% in two cases (27% andPatients (n ¼ 19) py
9075 (89; 86–93) —
12) 77720 (82; 59–93) o0.0001
5) 83715 (84; 75–93) o0.0001
79712 (82; 71–89) nsy
124) 48724 (43; 29–74) o0.0001
2) 88713 (93; 81–96) 0.002
6) 59718 (55; 45–70) o0.0001
).
hocytes CD4/CD8 % neutrophils % eosinophils
2 1.870.9 36.3718.5 0.871.3
–3) (1.6; 1.2–2.1) (30; 25.5–46.2) (0; 0–1)
9 2.772.2 59711 1.172.4




Table 4 Comparison of broncho-alveolar lavage and sputum differential cell count.
Total cell count % macrophages % lymphocytes CD4/CD8 % neutrophils % eosinophils
Patients (n ¼ 9)
BAL ( 105/mL) 3.570.7 63719 1176.1 1.371 16711 8.7710
(3.7; 3–4.1) (69; 62–73) (15; 6–16) (0.9; 0.7–2.1) (12; 11–21) (4; 2–11)
Sputum ( 106/mL) 7.674.9 32711 472.4 1.871.7 61710 273.6
(6.9; 3.2–10) (30; 25–34.5) (4; 2.5–4) (1.3; 0.4–2.6) (63; 59–64) (0; 0–2)
py o0.02 0.02 0.02 nsz 0.02 0.02
Data are expressed as mean value7SD (median value; IRQ 25–75).
yvs sputum samples, Wilcoxon test.
zns ¼ not significant.
Induced sputum in connective diseases lung involvement 138741%, respectively). As expected, neutrophils were however
more represented in sputa (p ¼ 0.02), while macrophages,
lymphocytes and eosinophils were higher in BAL samples
(p ¼ 0.02 in all instances). No difference of the CD4/CD8T
cell ratio was found in BAL in comparison to induced sputa.
No correlation was found between cell differentials in IS and
BAL samples (n ¼ 9).Discussion
In the present study, the assessment of airway involvement
in the course of CTD was evaluated by means of IS. Patients,
including cases affected by AR and SSc with no previous
history of lung diseases, were early recruited at the onset of
pulmonary symptoms. The most striking observation was
that IS samples from patients contained a significantly
higher percentage of neutrophils and a lower percentage of
macrophages compared to those obtained from healthy
subjects, while the total number of recovered cells showed
no differences. Induced sputa from healthy volunteers have
been described to be poor in eosinophils, lymphocytes and
epithelial cells, and rich in macrophages and neutrophils. To
date, although repeated sputum induction has been sug-
gested to have limited utility in serial assessment of
neutrophilic airway inflammation due to the rise in the
percentage of neutrophils over time,32 the baseline mean
values however range from 27.3% to 37.5%.32–35 Eosinophils
remain the most important and informative parameter
particularly in asthma and COPD patients, while neutrophils
can provide relevant information during infections as in
patients with COPD.36–38 On the contrary, owing to their low
number, lymphocytes in IS are seldom used as a disease
marker. However, with respect to ILD, D’Ippolito et al.17
have shown that IS samples from newly diagnosed and
untreated pulmonary sarcoidosis contains significant more
cells, and particularly more lymphocytes and epithelial
cells, when compared with sputa from healthy volunteers.
To our knowledge, this is the first study investigating the
inflammatory cell pattern in IS from patients affected by
CTD with early clinical evidence of any lung involvement and
in the absence of any evidence of respiratory infection. The
concept of granulocyte traffic to the lung is not new, as
neutrophils may play a critical role in the induction of tissue
injury through the release of oxidant, proteolitic and pro-
inflammatory mediators. In this issue, neutrophils and IL-8
levels have recently been found to be significantly increasedboth in alpha-1-antitrypsin PiMZ patients and in those
affected by idiopathic pulmonary fibrosis, being inversely
correlated with vital capacity in the latter.39,40 Interest-
ingly, in our series, sputum neutrophilic inflammation was
detected even in cases with mild alterations of lung function
parameters and no thoracic HRCT evidence of lung disease.
Indeed, no correlation between sputum neutrophilia and
lung function impairment or disease extension on HRCTwas
found. In addition and more surprisingly, even we found that
DLCOsb was early compromised in the majority of tested
patients (69%), there was not relation with sputum
neutrophilia. Although larger and follow-up studies are
further needed, this is however a quite interesting finding as
IS may represent a valuable tool for detecting early
abnormalities suggestive of subclinical lung involvement in
CTD patients. Such an observation is even stronger as, in a
similar manner, there is evidence that subclinical alveolitis
may be present in a significant number of asymptomatic
patients with both RA and SSc.2,5,8 Finally, the fact that
patients included in our study were undergoing anti-
rheumatic treatment has also to be taken into consideration
as most of them were receiving oral corticosteroids alone or
in combination with immunosuppressive drugs. While the
beneficial effect of inhaled corticosteroids on bronchial
eosinophilic inflammation in asthmatic patients has been
clearly established, results on sputum neutrophilia in
asthma and COPD patients in response to anti-inflammatory
therapies are contrasting.41–43 To date, it has been recently
reported that oral prednisolone, unlike inhaled budesonide,
increases the recruitment of neutrophils in the airway
submucosa of patients affected by mild asthma, while
eosinophils, neutrophils, and levels of IL-8 and myeloperox-
idase in IS do not change after treatment.44 Although in our
series we cannot exclude any treatment-related effect on
the bronchial cell profile of studied patients, the observa-
tion that such a pattern significantly differed from that of
healthy controls suggests that neutrophila may be a key
hallmark of CTD-related airway inflammation. Again, as
actually no more information is available in this issue,
further efforts have to be focused in untreated patients.
Sputum induction primarily samples the more proximal
airways containing neutrophil-rich secretions. To compare
cell differentials in IS to those of the deep lung, BAL was
carried out in 9 patients with thoracic HRCT evidence of
interstitial involvement. As expected, we found that
neutrophils were significantly increased in sputa than in
BAL samples, where they were however represented at
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88% of patients, being more than 20% in two cases. In a
similar fashion, a significant increase of neutrophils in IS
than in bronchial biopsies and BAL samples was shown in
sarcoidosis patients.17 On the contrary, we found that the
percentages of macrophages, lymphocytes and eosinophils
were higher in BAL samples, while in agreement with
previous observations the total cell number was lower than
that recovered from IS.10 Finally, we found a lack of
correlation of the differential cell counts in the two
different samples, which suggests that IS and BAL reflect
different compartments of inflammation.
Aims of future studies could be to determine whether the
non invasive assessment of airway inflammation adds
significant information to that provided by the clinical
history, lung function testing and thoracic HRCT data in CTD
patients and whether this results in a relevant improvement
concerning the patient’s management. Although IS is a non-
invasive diagnostic tool, as it was well tolerated and
preferred to BAL by all patients in our study, no specific
efforts have been carried out on the safety and functional
effects of IS in patients with ILD and particularly in those
with CTD-related lung involvement. In conclusion, IS
procedure is far safer and easier to perform with no
limitation to be frequently repeated. We suggest that it
can be used as a complementary tool to lung function
testing, HRCT and BAL in the early clinical assessment of
CTD-related lung disorders. However, future studies are
needed to better characterize airway inflammation in these
patients and evaluate whether IS can replace more invasive
procedures, i.e. BAL and HRCT, for disease monitoring and
treatment follow-up.
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